Currently, there are 9.87M common shares owned by the public and among those 9.31M shares have been available to trade.
The company’s stock has a 5-day price change of -40.68% and -76.03% over the past three months. IBIO shares are trading -71.43% year to date (YTD), with the 12-month market performance down to -60.45% lower. It has a 12-month low price of $0.84 and touched a high of $6.89 over the same period. IBIO has an average intraday trading volume of 638.13K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -71.09%, -81.32%, and -74.32% respectively.
Institutional ownership of iBio Inc (NASDAQ: IBIO) shares accounts for 26.65% of the company’s 9.87M shares outstanding.
It has a market capitalization of $6.91M and a beta (3y monthly) value of 1.55. The earnings-per-share (ttm) stands at -$2.70. Price movements for the stock have been influenced by the stock’s volatility, which stands at 20.99% over the week and 20.34% over the month.
Earnings per share for the fiscal year are expected to increase by 60.55%, and 13.52% over the next financial year. EPS should shrink at an annualized rate of 45.01% over the next five years, compared to 57.55% over the past 5-year period.
Looking at the support for the IBIO, a number of firms have released research notes about the stock. Chardan Capital Markets stated their Buy rating for the stock in a research note on May 28, 2024, with the firm’s price target at $5. JMP Securities coverage for the iBio Inc (IBIO) stock in a research note released on November 29, 2021 offered a Mkt Outperform rating with a price target of $1.50. Cantor Fitzgerald was of a view on January 22, 2021 that the stock is Overweight, while Alliance Global Partners gave the stock Buy rating on June 26, 2020, issuing a price target of $2.55.
